

21 February 2020  
ASX Code: MXC

## 85% Increase in Order Volume of New Prescription Medicine Products to Australia, for Immediate Delivery



**MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company')**, a European based 'Seed to Medicine' bio-pharma company specialising in the development and production of phytocannabinoid-derived medicines, is pleased to announce that it has received an 85% increase to its January purchase order volume over the past week, from 2,000 to 3,700 units for the immediate production and delivery of its Mercury Pharma line of proprietary prescription medicinal products. The Mercury Pharma line has been developed to deliver a cost focused medicine for Australian and New Zealand patients, and is already receiving strong patient demand.

Upon delivery, this order will lead to a significant increase to the number of prescriptions issued to date, more than doubling the total to over 4,500. The increased order volume demonstrates the immediate market demand for the affordable Mercury Pharma line of products from patients in Australia and New Zealand.

The increased 3,700 unit order for Mercury Pharma line and white label products will deliver over A\$430,000 in revenue to the Company. The order of an additional 1,700 units adds approximately A\$200,000 to the contract value, directly increasing the Company's Q1 revenues.

### Key Highlights:

- The Company launched the Mercury Pharma brand in January 2020 and has immediately generated a significant increase in purchase orders due to quality and competitive pricing
- The Mercury Pharma line is being produced specifically for the Australian and New Zealand markets only
- The Mercury Pharma line has been developed following feedback from patients and prescribing physicians that one of the biggest hurdles to accessing and continuing as patients is the cost of phytocannabinoid derived medication currently available
- The Mercury Pharma line reinforces MGC Pharma's strategy to provide affordable, standardised phytocannabinoid medicines to patients globally
- Purchase orders for a total of 3,700 units received for January and February 2020, totalling revenue of A\$430,000 representing a considerable impact on short term revenues, which the Company expects to grow from this new product line
- Import permits from the Australian Office of Drug Control received for the first shipment and expected to be completed in late February/early March
- Upon prescription, this will more than double the current total of MGC Pharma medicines prescribed to date
- In Australia, Mercury Pharma products will initially be supplied, under current distribution agreements, by Cannvalate Pty Ltd



Figure 1: Mercury Pharma MP100 Bottle

A  
S  
X  
  
R  
E  
L  
E  
A  
S  
E

The order consists of a range of Mercury Pharma products, mainly MP100, a 100mg/mL cannabidiol (CBD) solution, and includes a white label product. All products will be prescribed by health care professionals in Australia and New Zealand, distributed by Australian medicinal cannabis distribution and logistics specialist Cannvalate Pty Ltd, and several distribution partners in New Zealand.

**Roby Zomer, Co-founder and Managing Director of MGC Pharma, commented:** “Following the launch of our new brand, Mercury Pharma, we are delighted to see order numbers increase significantly over the last few weeks and continue to see a material impact on our short-term revenues. Upon delivery to patients in the coming weeks we will see a more than doubling of current total of MGC Pharma medicines prescribed to date to over 4,500, which we expect to grow rapidly over the coming months with access to new markets opening for our cannabinoid-based medicines.”

--Ends--

**Authorised for issue by the Board, for further information, please contact:**

**UK IR/Media Advisors**

Catherine Leftley/Megan Dennison  
St Brides Partners Ltd  
+44 (0) 207 236 1177  
[catherine@stbridespartners.co.uk](mailto:catherine@stbridespartners.co.uk)  
[megan@stbridespartners.co.uk](mailto:megan@stbridespartners.co.uk)

**MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MGC Pharma

MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its ‘Seed to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. MGC Pharma has a number of research collaborations with world renowned academic institutions, and recent research conducted in collaboration with the National Institute of Biology and University Medical Centre Ljubljana, highlighted the positive impact of using specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. In order to meet the demands of becoming a key global supplier the company is constructing a 15,720m<sup>2</sup> GMP state of the art facility in Malta.

Follow us through our social media channels    